This failure combined with the significant uncertainty around the Vifor acquisition is not great.
There is earnings growth coming out of the covid period, but unfortunately there is suspect capital allocation going on at CSL, the ROIC has collapsed.
Vifor is a massive bet that needs to pay off, but honestly I would not be surprised if that is written down by some amount in the coming years. Most big acquisitions destroy value.
Ann: Top-line Results from the Phase 3 AEGIS-II Trial, page-14
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$286.95 |
Change
1.220(0.43%) |
Mkt cap ! $138.3B | |||
| Open | High | Low | Value | Volume |
| $286.25 | $287.25 | $286.03 | $5.825M | 20.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12 | $286.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $287.02 | 136 | 4 |
View Market Depth
| Last trade - 10.08am 07/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |